Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | NK-CAR immunotherapy: the next steps

Evelyn Ullrich • 1 Sep 2020
EBMT 2020
General CAR-T NK-Cell Therapy

Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, discusses the next steps with respect to NK-CAR immunotherapy, highlighting a multicenter Phase II study and issues for future studies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Evelyn Ullrich

2:08
Advances in gene engineering technologies for NK cell-based immunotherapy
Evelyn Ullrich • 24 Apr 2023
2:17
Immunity of patients with multiple myeloma after vaccination against COVID-19
Evelyn Ullrich • 5 Dec 2022
3:09
Using CRISPR/Cas9 gene editing to generate NKG2A-knockout CD33-CAR-NK cells for the treatment of AML
Evelyn Ullrich • 5 Dec 2022
4:20
An insight into the use of CAR-NKs for the treatment of AML
Evelyn Ullrich • 15 Mar 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals